» Articles » PMID: 20603617

The Unexpected Role of Lymphotoxin Beta Receptor Signaling in Carcinogenesis: from Lymphoid Tissue Formation to Liver and Prostate Cancer Development

Overview
Journal Oncogene
Date 2010 Jul 7
PMID 20603617
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

The cytokines lymphotoxin (LT) alpha, beta and their receptor (LTbetaR) belong to the tumor necrosis factor (TNF) superfamily, whose founder-TNFalpha-was initially discovered due to its tumor necrotizing activity. LTbetaR signaling serves pleiotropic functions including the control of lymphoid organ development, support of efficient immune responses against pathogens due to maintenance of intact lymphoid structures, induction of tertiary lymphoid organs, liver regeneration or control of lipid homeostasis. Signaling through LTbetaR comprises the noncanonical/canonical nuclear factor-kappaB (NF-kappaB) pathways thus inducing chemokine, cytokine or adhesion molecule expression, cell proliferation and cell survival. Blocking LTbetaR signaling or Fcgamma-receptor mediated immunoablation of LT-expressing cells was demonstrated to be beneficial in various infectious or noninfectious inflammatory or autoimmune disorders. Only recently, LTbetaR signaling was shown to initiate inflammation-induced carcinogenesis, to influence primary tumorigenesis and to control reemergence of carcinoma in various cancer models through distinct mechanisms. Indeed, LTbetaR signaling inhibition has already been used as efficient anti-inflammatory, anti-cancer therapy in some experimental models. Here, we review the pleiotropic functions attributed to LT, the effects of its deregulation and extensively discuss the recent literature on LT's link to carcinogenesis.

Citing Articles

Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling.

Piao W, Wu L, Xiong Y, Zapas G, Paluskievicz C, Oakes R Nat Commun. 2024; 15(1):10468.

PMID: 39622857 PMC: 11612289. DOI: 10.1038/s41467-024-54874-y.


Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer.

Croft M, Salek-Ardakani S, Ware C Nat Rev Drug Discov. 2024; 23(12):939-961.

PMID: 39448880 DOI: 10.1038/s41573-024-01053-9.


LTBR acts as a novel immune checkpoint of tumor-associated macrophages for cancer immunotherapy.

Wang L, Fan J, Wu S, Cheng S, Zhao J, Fan F Imeta. 2024; 3(5):e233.

PMID: 39429877 PMC: 11487550. DOI: 10.1002/imt2.233.


LUBAC enables tumor-promoting LTβ receptor signaling by activating canonical NF-κB.

Chen Y, Rieser E, Bhamra A, Surinova S, Kreuzaler P, Ho M Cell Death Differ. 2024; 31(10):1267-1284.

PMID: 39215104 PMC: 11445442. DOI: 10.1038/s41418-024-01355-w.


ncRNA-mediated SOX4 overexpression correlates with unfavorable outcomes and immune infiltration in hepatocellular carcinoma.

Li J, Sun X, Lv M, Han Z, Zhong X, Zhang W BMC Gastroenterol. 2024; 24(1):265.

PMID: 39143462 PMC: 11323613. DOI: 10.1186/s12876-024-03346-0.